Aclaris Therap | 10-Q: FY2025 Q3 Revenue Beats Estimate at USD 3.299 M

Revenue: As of FY2025 Q3, the actual value is USD 3.299 M, beating the estimate of USD 1.405 M.

EPS: As of FY2025 Q3, the actual value is USD -0.12, beating the estimate of USD -0.135.

EBIT: As of FY2025 Q3, the actual value is USD -18.97 M.

Therapeutics Segment

• Revenue: $2.814 million for the three months ended September 30, 2025, and $5.159 million for the nine months ended September 30, 2025.
• Research and Development Expenses: $13.242 million for the three months ended September 30, 2025, and $36.722 million for the nine months ended September 30, 2025.
• Licensing Expenses: $1.911 million for the three months ended September 30, 2025, and $4.256 million for the nine months ended September 30, 2025.
• Revaluation of Contingent Consideration: $100 thousand for the three months ended September 30, 2025, and $1.900 million for the nine months ended September 30, 2025.

Contract Research Segment

• Revenue: $485 thousand for the three months ended September 30, 2025, and $1.372 million for the nine months ended September 30, 2025.
• Cost of Revenue: $4.454 million for the three months ended September 30, 2025, and $11.983 million for the nine months ended September 30, 2025.

Cash Flow

• Net Cash Used in Operating Activities: - $33.982 million for the nine months ended September 30, 2025.
• Net Cash Provided by Investing Activities: $37.996 million for the nine months ended September 30, 2025.
• Net Cash Used in Financing Activities: - $3.328 million for the nine months ended September 30, 2025.

Future Outlook and Strategy

• Core Business Focus: The company plans to continue the development of its product candidates and pursue discovery programs, expecting to incur significant expenses and operating losses for the foreseeable future.
• Non-Core Business: The company is seeking a global development and commercialization partner for its lepzacitinib program (excluding Greater China).
• Priority: The company believes its existing cash, cash equivalents, and marketable securities are sufficient to fund its operating and capital expenditure requirements for a period greater than 12 months from the date of issuance of its condensed consolidated financial statements.